Keywords
Last Name
Institution

David Becton

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPediatrics, College of Medicine
DivisionPeds Hematology
Address ACH Sturgis Building
800 Marshall Street
Mail Slot # 512-10
Little Rock AR 72202
Phone501-364-1494
vCardDownload vCard

    Collapse Research Funds 
    Collapse principal investigator
    Funding Agency: COG - Title: AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia - Start Date: 2017-09-01

    Pass Through Agency: Children's Hospital of Philadelphia - Funding Agency: The Children's Oncology Group Foundation - Title: EVERYCHILD (APEC14B1) - Start Date: 2017-04-01

    Pass Through Agency: COG - Funding Agency: Bayer Inc. - Title: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD - Start Date: 2016-09-01

    Pass Through Agency: COG - Funding Agency: Incyte Corporation - Title: A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia - Start Date: 2016-08-01

    Pass Through Agency: COG - Funding Agency: Amgen, Inc. - Title: Risk-Stratified Randomized Phase III Testing of Blinatumomab in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) - Start Date: 2016-06-01

    Funding Agency: COG - Title: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents - Start Date: 2016-03-21

    Pass Through Agency: Children's Hospital of Philadelphia - Funding Agency: - Title: A Phase 2, Multicenter, Single-Arm, Open Label Study to Evaluate the Activity , Safety and Pharmacokinetics of Lenalidomide in Pediatric Subjects from 1 to 18 YO with Relapsed or refractory Acute Myeloid Leukemia - Start Date: 2015-10-06

    Pass Through Agency: NCI-Childrens Oncology Group - Funding Agency: Novartis Pharmaceuticals Corporation - Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors - Start Date: 2015-04-06

    Funding Agency: COG - Title: COG: AALL1421- A dose confirmation and Pharmacokinetic study of Asparec Administered as IV infusion in children and young adults with acute lymphoblastic leukemia/lymphoblastic lymphoma following hypersensitivity to pegaspargase - Start Date: 2014-11-01

    Funding Agency: COG - Title: Health Effects after Anthracycline and Radiation Therapy (HEART):Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy - Start Date: 2014-11-01

    Funding Agency: COG - Title: A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor, in Children with Recurrent/Refractory Solid Tumors and Leukemias. ADVL0921 - Start Date: 2014-09-01

    Funding Agency: COG - Title: NIH National Clinical Trials Network Per Case Reimbursement - Start Date: 2014-09-01

    Funding Agency: COG - Title: COG #AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Duction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) - Start Date: 2013-02-01

    Funding Agency: COG - Title: COG AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD - Start Date: 2013-02-01

    Funding Agency: COG - Title: COG# ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-Cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Start Date: 2013-02-01

    Funding Agency: Pfizer - Title: A Phase II Study of Sunitinib in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients - Start Date: 2013-01-01

    Funding Agency: Bristol Myers Squibb Pharmaceutical Research Institute - Title: A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia - Start Date: 2012-12-01

    Pass Through Agency: Children's Hospital of Philadelphia - Funding Agency: St. Baldrick's Foundation - Title: St. Baldrick's Foundation Grant - Start Date: 2012-04-26

    Funding Agency: COG - Title: COG- AALL1131_A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia Testing Clofarabine in the Very High Risk Stratum - Start Date: 2012-03-30

    Pass Through Agency: Children's Hospital of Philadelphia - Funding Agency: National Institutes of Health - Title: NIH COG Chair Grant: Workload Intensity - Start Date: 2012-03-01

    Pass Through Agency: Children's Hospital of Philadelphia - Funding Agency: National Institutes of Health - Title: NIH COG Chair Grant: Per Case Reimbursement - Start Date: 2012-03-01

    Funding Agency: NCI-Childrens Oncology Group - Title: Cancer Trials Support Unit: Phase II Supplemental Payments - Start Date: 2012-01-01


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 Oct; 34(10):1716-1724. PMID: 26867804.
      View in: PubMed
    2. Stine KC, Wahl EC, Liu L, Skinner RA, Vanderschilden J, Bunn RC, Montgomery CO, Suva LJ, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Lumpkin CK. Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res. 2014 Mar; 32(3):464-70. PMID: 24259375; PMCID: PMC4080883.
    3. Mian A, Becton D, Saylors R, James L, Tang X, Bhutta A, Prodhan P. Biomarkers for risk stratification of febrile neutropenia among children with malignancy: a pilot study. Pediatr Blood Cancer. 2012 Aug; 59(2):238-45. PMID: 22535591.
      View in: PubMed
    4. Cash T, Becton D, Mian A. Cardiac myeloid sarcoma: a case report and review of literature. J Pediatr Hematol Oncol. 2011 Oct; 33(7):e330-2. PMID: 21941137.
      View in: PubMed
    5. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW, ICA-17043-10 Study Investigators. Imporovements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011; 153(1):92-104.
    6. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, Children's Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-1323.
    7. Pollard JA, Alonzo TA, Gerbina R, Ho PA, Zeng R, Becton David L. Prevalence and prognostic significance of KIT mutations in pediatric core binding factor AML patients enrolled on serial pediatric cooperative trials for de novo AML. Blood J of Amer. Soc. Hem. 2010; 115(12):2372-2379.
    8. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25; 115(12):2372-9. PMID: 20056794; PMCID: PMC2845895.
    9. Stine KC, Becton DL. Bleeding disorders: when is normal bleeding not normal? J Ark Med Soc. 2009 Aug; 106(2):40-2. PMID: 19715248.
      View in: PubMed
    10. Mian A, Becton D, Blackall DP, James SH, Berman DM, Owusu JA, Turner C, Givner LB, Shetty AK. Index of suspicion. Pediatr Rev. 2009 Apr; 30(4):139-45. PMID: 19339388.
      View in: PubMed
    11. Becton David L, J Powell, P Kouides, K Andersen, B Konkle, J Dipaola, J Seigel. Factor VIII Prophylaxis for Adult Patients with Severe Hemophilia A: Results of a US Survey of Attitudes and Practices. Haemophilia. 2009.
    12. Horan J, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton DL. Matched Related Bone Marrow Transplantation for Pediatric AML: An Analysis of the Impact of Disease Risk and Timing of Transplantation on its Efficacy: A Report from the Children's Oncology Group. J Clin Oncol. 2008; 26(35):5797-801.
    13. Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5797-801. PMID: 18955460; PMCID: PMC2645105.
    14. Blanchette VS, Shapiro AD, Liesner RJ, Hernandez Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM, RAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008; 6(8):1319-26.
    15. O'Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 20; 26(3):414-20. PMID: 18202418; PMCID: PMC3897300.
    16. Obrien J, Taub J, Chang M, Massey G, Stine K, Raimondi S, Becton DL. Cardiomyopathy in Childen with Down Syndrome Treated for Acute Myeloid Leukemia: A Report from the Children's Oncology Group Study POG 9421. J Clinc Onc. 2008; 26(3):414-420.
    17. Stine KC, Saylors RL, Saccente CS, Becton DL. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost. 2007 Apr; 13(2):161-5. PMID: 17456625.
      View in: PubMed
    18. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol. 2007 Apr; 29(4):216-21. PMID: 17414562.
      View in: PubMed
    19. Walsh C, Andersen J, Becton DL, DiPaola J, Konkle B, Kouides P, Et al. Prophylaxis for Adults with Severe Hemophilia: A Compelling Need for Evidence-Based Guidelines. Haemophilia. 2007.
    20. Savasan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro durg sensitivity and outcome. Leuk Lymphoma. 2006; 47(10):2076-83.
    21. Savasan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma. 2006 Oct; 47(10):2076-83. PMID: 17071479.
      View in: PubMed
    22. Becton DL, Dahl GV, Ravindranath Y, Chang MN. Randomized use of Cyclosporin A (CSA) to Modulate P-glycoprotein in Children with AML in Remission: Pediatric Oncology Group Protocol 9421. Blood. 2006; 107(4):1315-24.
    23. Becton DL, Hamilton TA, Weiel JE, Somers SD, Adams DO. IN PRESS. Activation of Macrophages: Identification of Molecular Elements Involved in Regulation. 2006.
    24. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006 Feb 15; 107(4):1315-24. PMID: 16254147; PMCID: PMC1895393.
    25. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006 Feb 15; 107(4):1570-81. PMID: 16249385; PMCID: PMC1895418.
    26. Becton DL. Childhood luekemia--success and challenges. J Ark Med Soc. 2005 Sep; 102(3):79-80. PMID: 16184810.
      View in: PubMed
    27. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 2004 Nov 01; 104(9):2646-54. PMID: 15251987.
      View in: PubMed
    28. Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4. PMID: 15170896.
      View in: PubMed
    29. Lacayo N, Mashinchi S, Becton DL, Et al. FLT3 Mutations with Good Clinical Outcome are Identified by Gene Expression Profiles at Diagnosis in de novo Childhood AML. Blood. 2004; 104:2646-2654.
    30. Stine KC, Saylors RL, Saccente S, Becton DL. Efficacy of Continuous Infusion 2-CDA (Cladribine) in Pediatric Patients with Langerhans Cell Hystiocytosis. Ped Blood & Cancer. 2004; 43(1):81-84.
    31. Stine KC, Becton DL, Dahl GV, Ravindranath Y, Raimondi S, Behm FG, Chang M, Weinstein H. Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group Study 9421 (now Children's Oncology Group). American Society of Hematology. 2004.
    32. Stine KC, Saylors RL, Saccente S, Becton DL. Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol. 2003 Jul; 41(1):77-8. PMID: 12764753.
      View in: PubMed
    33. Stine KC, Saylors RL, Saccente SL, Becton DL. 2-chlorodeoxyadenosine for the Treatment of Refractory or Recurrent Langerhan's Cell Histiocytosis in Pediatric Patients. XIX Annual Meeting of the Histiocyte Society. 2003; 43 (2):203.
    34. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002 Mar 15; 20(6):1617-24. PMID: 11896112.
      View in: PubMed
    35. Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P. Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: application to a pediatric oncology clinic. Med Pediatr Oncol. 2002 Mar; 38(3):183-6. PMID: 11836718.
      View in: PubMed
    36. Stine KC, Warren BA, Becton DL. IL-12 Induces IL-12 Receptor (R) Up-regulation in Ewing's Sarcoma Cell Lines Prior to Apoptosis. Pediatric Academic Societies. 2002; 24 (3):1360.
    37. Stine KC, Warren BA, Saylors RL, Becton DL. IL-12 Induces IL-12 Receptor (IL-12R) Expression in Sensitive AML Cell Lines. Pediatric Academic Societies. 2002; 24 (3):1359.
    38. Furman WL, Stewart CF, Becton DL. A Protracted Intermittent Schedule of Topotecan in Children with Refractory Acute Leukemia: A Pediatric Oncology Group Study. J Clinc Onc. 2002; 20(6):1617-24.
    39. Ge Y, Jenson T, Joiner SJ, Becton DL, Et al. High Frequency of the 844ins 68 Cystathionine-Synthase Gene Variant in Down Syndrome Children with Acute Myeloid Leukemia. Leukemia. 2002; 16(11):2339-41.
    40. Verneris MR, McDougal IR, Becton DL. Thyroid Carcinoma After Successful Treatment of Osteosarcoma: A Report of Three Cases. J Ped Hem/Onc. 2001; 23(5):3125.
    41. Leissinger C, Becton DL, Cornell C, Gill JC. Stimate (desmopressin acetqte) Nasal Spray, 1.5 mg/ml, for Preventionand Treatment of Bleeding in Patients with Mild Hemophilia A, Mild or Moderate Type I Von Willebrand Disease and Symptomatic Carriers of Hemophilia A. Hemophilia. 2001; 7(3):258-66.
    42. Stine KC, Warren BA, Saylors RL, Becton DL. IL-12 Induces IL-12 Receptor (IL-12R) Expression on IL-12 Sensitive Cell Lines. 2001; 98 (11):4609.
    43. Becton DL, Ravindranath Y, Dahl GV, Berkow RL, Chang M, Stine KC, Et al. A Phase III Study of Intensive Cytarabine (Ara-C) Induction Followed by Cyclosporine (CSA) Modulation of Drug Resistance in De Novo Pediatric AML: POG 9421. 43rd Annual American Society of Hematology. 2001; 98 (11):1929.
    44. Becton DL, Saylors RL, Morris J, Saccente SL, Stine KC. Treatment of Bleeding with rFVIIa (NovoSeven) in Four Diverse Cases. 2001; 98 (11):1104.
    45. Haga SB, Fu S, Becton DL. BP1, a New Homeobox Gene, is Frequently Expressed in Acute Leukemia. Leukemia. 2000; 14(11):1867-75.
    46. Stine KC, Saylors RL, Becton DL. 2-Cholordeoxyadenosine (2-CDA) for the Treatment of Refractory or Recurrent Langerhans Histiocytosis in Pediatric Patients. 1999; 12 (4):52.
    47. Parham DM, North P, Quiggins C, Ready R, Stine KC, Becton DL. Comparison of Manual vs. Automated Leukocyte Counts for Determination of the Absolute Neutrophil Count. 1999; 12 (4):52.
    48. Taub JW, Huang X, Becton DL. Expression of Chromosome 21 - Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrom and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin. Blood. 1999; 94(4):1393-400.
    49. Savasan S, Buck S, Becton DL, Et al. Cytotoxicity Assessment by Quantiating Drug-Induced Apoptosis and Drug Resistance Patterns in Childhood AML. Annual meeting American Society of Hematology. 1999; 94:268a.
    50. Seibert JJ, Glasier CM, Becton DL. Transcranial Doppler (TCD), MRA, and MRI as a Screening Examination for Cerebrovascular Disease in Patients with Sickle Cell Anemia. An Eight Year Study. Ped Rad. 1998; 28(3):138-42.
    51. Stine KC, Warren BA, Becton DL. IL-12 augments NK lysis of AML cell lines. Leukemia. 1998; 12(8):1204-6.
    52. Taub JW, Huang X, Becton DL, Et al. Difference in Expression of Chromiosiome 21 in Childhood AML. American Society of Hematology. 1997; 90:2212a.
    53. Becton DL, Thompson A, Bergman GG. Safety and Efficacy of Stimate (Desmopressin Acutate, 1.5 mg/ml) Nasal Spray in Patients with Mild to Moderate von Willebrand's Disease. ISTH. 1997.
    54. Stine KC, Becton DL, Warren BA, Weinstein H, Behm F. IL-1 and IL-12 Augment Apoptosis of Cryopreserved Pediatric AML Blasts. American Society of Hematology. 1997; 90:1235a.
    55. Stine KC, Saylors RL, Sawyer JR, Becton DL. Secondary AML (sAML) following "safe" exposure to etoposide. J Clinc Onc. 1997; 15,:1583-1586.
    56. Becton DL, Cornell C, Gill J, Et al. Evaluation of the Efficacy and Safety of Stimate. American Society of Hematology. 1997; 90:134a.
    57. Lacayo N, Lum BL, Johnson S, Villena J, Becton DL, Weinstein HJ, Et al. Pharmacokinetics of Etoposide and Mitoxantrone in a Controlled Trial of Cyclosporin as an MDR Modulator in Acute Myeloid Leukemia (Pediatric Oncology Group). ASCO. 1997.
    58. Taub JW, Stout ML, Becton DL. Myeloblasts from Down Syndrome Children with Acute Myeloid Leukemia have Increased In Vitro Sensitivity to Cytarabine and Daunorubicin. Leukemia. 1997; 11(9):1594-95.
    59. Ogden AK, Hurwitz C, Becton DL, Stine KC. Combination Therapy with Idarubicin (IDA) and Cladribine (CDA) in Pediatric Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML). ASCO. 1997; 16:1870a.
    60. Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhagae rather than thrombosis: The "Hemorrhagic lupus anticoagulant syndrome". J Peds. 1997; 130::998.
    61. Stine KC, Saylors RL, Williams L, Becton DL. 2-Chlorodeoxyadenosine is an effective agent in high risk pediatric Langerhan's Cell Histiocytosis. Ped Onc. 1997; 29::288-292.
    62. Bjornson AB, Becton DL. Serotype-Specific IgG Antibody Responses to Pneumococcal Polysaccharide Vaccine in Children with Sickle Cell Anemia: Effects of Continued Penicillin Prophylaxis. J Peds. 1996; 129,:788.
    63. Taub JW, Stout M, Buck SA, Vega RA, Becton DL, Ravindranath Y. Enhanced in vitro Sensitivity of Down Syndrome Myeloblasts to Cytarabine and Daunorubicin Utilizing the MTT Colorimetric Assay. ASCO. 1996.
    64. Mannucci PM, Chediak J, Byrmes J, Kessler C, Marciniak E, Hanna W, Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of Von Willebrand's Disease. ISTH. 1996.
    65. Mannucci PM, Chediak J, Byrmes J, Kessler C, Marciniak E, Hanna W, Retzios AP, Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of Von Willebrand's Disease. American Society of Hematology. 1996.
    66. Stine KC, Warren BA, Becton DL. IL-12 Mediates Apoptosis of KG1a, but not K562, or HL-60 Cell Lines. ASCO. 1995.
    67. Falletta JM, Becton DL, Et al. Discontinuation of Penicillin Prophylaxis in Children. J Peds. 1995; 127,:685.
    68. Stine KC, Williams L, Saylors RL, Becton DL. 2-Cholordeoxyadenosine (2-CDA) for the Treatment of Refractory or Recurrent Langerhans Histiocytosis in Pediatric Patients. American Society of Hematology. 1995.
    69. Stine KC, Warren BA, Becton DL. Apoptosis Induced by IL-6 or IL-12 Measured by DNA Electrophoresis and in situ End Labeling in Leukemia. 1995; 86:743a.
    70. Mannucci PM, Chediak J, Byrmes J, Kessler C, Marciniak E, Hanna W, Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of Von Willebrand's Disease. American Society of Hematology. 1995.
    71. Stine KC, Warren BA, Becton DL. In Vitro Effects of Interleukin-12 (IL-12) on Acute Non-Lymphocytic Leukemia (ANLL). Annual meeting American Society of Hematology. 1994; 84:200a.
    72. Becton DL, Manno C, Green D, Gilchrist G, Kulkarni R, Priest J, Et al. Viral Safety of an Affinity-Purified Coagulation Factor IX Concentrate (Alphanine SD). American Society of Hematology. 1994; 84:776a.
    73. Stine KC, Longee D, Kletzel M, Becton DL. Autologous Bone Marrow Transplant (ABMT) with Unpurged Marrow in Children with Neuroblastoma (NB). 1994; 13:1460a.
    74. Haut PR, Schutze GE, Stine KC, Becton DL. Use of Varicella Zoster Immune Globulin in Immunocompromised Patients. 1993; 41 (4):783a.
    75. Hults C, Stine KC, Longee D, Becton DL. Prospective Analysis of IL-6 Levels in Patients (PT) with Hemophilia. 1993; 41 (4):730a.
    76. Seibert JJ, Miller SF, Becton DL, Et al. Cerebrovascular Disease in Symptomatic and Asymptomatic patients with Sickle Cell Anemia: Screening and Duplex Transcranial Doppler US-Correlation with MR Imaging and MR Angiography. Neurorad. 1993; 189,:457-466.
    77. Becton DL, Weinstein HJ, Ogden A, Berkow R, Krischer J. High-Dose Ara-C (HDA), Daunorubicin (d), Thioguanine (T), and VP-16 for Remission Induction in Untreated AML in Children. 1993; 82:766a.
    78. Schexnayder SM, Stine KC, Webster PA, Heulitt MJ, Becton DL. A Technique for Automated Exchange Transfusion in Children and Young Adults. 1993; 41 (4):783a.
    79. Becton DL, Miller C, Cunniff C. Control of Bleeding in Ehlers-Danlos Syndrome with DDAVP. Congress of International Society of Hemostasis and Thrombosis. 1993; 69 (6): 1804A.
    80. Klasner A, Longee D, Stine KC, Becton DL. Deficiency of Vitamin K-Dependent Coagulation Factors. 1993; 41 (4):803a.
    81. Becton DL, Stine KC, Longee DC. Clinical Heterogeneity of the Lupus Anticoagulant in Children. 1993; 82:2440a.
    82. Becton DL, Ford J, McAdory B, Stine K, Longee D. Simple Transfusion and Hydration for Children with Sickle Cell Disease (SCD) Undergoing General Anesthesia for Surgical Procedures. 1992; 80:1537A.
    83. Becton DL, Seibert J, Berry DH, James CA, Glasier CM, Kirby RJ. Comprehensive Evaluation for Cerebro-Vascular Disease (CVD) in Children with Sickle Cell (SCD) with Duplex Transcranial Doppler (DTD), MRI and MRA. American Society of Hematology. 1992; 80:23A.
    84. Kletzel M, Elser J, Becton DL, Chadduck W, Miller C. Head Bleeding in Infants with Hemophilia: causes and management. Amer J Dis in Child. 1989; 143,:1107-1110.
    85. Becton DL, Roberts B, Bryles P. Anti-proliferative Effects of Iron Chelators on Human Myeloid Leukemia Cell Lines. Proceedings American Association for Cancer Research. 1989; 30:2294.
    86. Becton DL, Roberts B. Anti-leukemic effect of deferroxamine. Cancer Res. 1989; 49::4809-4812.
    87. Becton DL, Bryles P. Effects of Iron Chelators on Human Myeloid Leukemia. International Symposium on Oral Chelation in the Treatment of Thalassemia and Other Diseases. 1989; 54, Vol. I.
    88. Becton DL, Raymond L, Thompson C, Berry DH. Acute phase reactants in sickle cell patients. J Peds. 1989; 115,:99-103.
    89. Becton DL, Bryles P. Deferroxamine inhibition of neuroblastoma viability and proliferation. Cancer Res. 1988; 48::7189-7192.
    90. Becton DL, Hlavaty T, Roberts B. Cytoxicity and Antiproliferative Effects of Deferroxamine Against Cells from Children with Acute Myeloid Leukemia. 1988; 72:664A.
    91. Becton DL, Kletzel M, Golladay ES, Hathaway G, Berry DH. Experience with an Implanted Port System in Sixty-Six Children with Cancer. Cancer. 1988; 61::376-378.
    92. Becton DL, Bryles P. Antileukemic Effects of Deferroxamine. Society for Pediatric Research. 1988; 36:68A.
    93. Kletzel M, Becton DL, Hutchins L. Phase I/II trial of High Dose Cytoxan, Continuous Infusion Vincristine and Escalating Doses of VP-16 and TBI with Autologous Bone Marrow Transplantation for Children. 1988.
    94. Becton DL, Roberts B. Deferroxamine Inhibition of Proliferation and DNA Synthesis in Human Myeloid Leukemia Cell Lines. 1988; 72:665A.
    95. Becton DL, Arnold WC, Kletzel M, Berry DH. Thrombotic thrombocytopenic purpura in an asplenic patient with hereditary spherocytosis. Amer J Pediatr Hematol Oncol. 1988; 10::5-8.
    96. Becton DL, Hockenberry MJ, Kinney TR. Isolated vocal cord hematoma in Factor VIII deficiency. Southern Med J. 1987; 80::272.
    97. Becton DL. Translocation of Protein Kinase C is Not Sufficient to Induce Macrophage Differentiation in HEL Erythroleukemia Cells. American Society of Hematology. 1987; 70: 1:619.
    98. Becton DL, Kurtzberg J, Friedman HS, Chaffee S, Kinney TR, Falletta JM. Treatment of Familial Erythrophagocytic Lymphohistiocytosis with VP-16; Relapse Therapy with AZQ. Med Pediatr Oncol. 1987; 15::58-61.
    99. Becton DL, Golladay ES, Kletzel M, Berry DH. Experience with Implanted Port System in Children with Cancer. Society for Pediatric Research. 1987.
    100. Becton DL, Armstrong B, Friedman HS. Endocarditis associated with long-term right atrial catheterization. Pediatr Hematol Oncol. 1987; 4::131.
    101. Becton DL, Friedman HS, Kurtzberg J, Chaffee S, Falletta JM, Kinney TR. Severe Mycoplasma Pneumonia in Three Siblings with SS Hemoglobin. Pediatr Hematol Oncol. 1986; 3::259.
    102. Hamilton TA, Somers SD, Becton DL, Celada A, Schreiber RO, Adams DO. Analysis of deficiences in IFN-gamma mediated priming for tumor cytotoxicity in peritoneal macrophage from A/J mice. J Immunol. 1986; 137::3367.
    103. Becton DL. Pediatric Hematology/Oncology: Perspectives in Care. Childhood Neutropenias. 1986; 18, Part II.
    104. Becton DL. Pediatric Hematology/Oncology: Perspectives in Care. Polycythemia in Children. 1986; 17, Part II.
    105. Becton DL, Schultz WH, Kinney TR. Neutropenia Secondary to Copper Deficiency in a Patient on Chronic Ambulatory Peritoneal Dialysis. J Pediatr. 1986; 108::735.
    106. Becton DL, Kinney TR. Severe Hemolytic Anemia in an Infant with Anti-Vel Antibody. Von Sanguinis. 1986; 51::108.
    107. Somers SD, Becton DL, Hamilton T. Interferon-y Modulates Protein Kinase C in Murine Peritoneal Macrophages. J Biol Chem. 1985; 260:(3):1378.
    108. Becton DL, Hamilton TA, Kinney TR, Adams DO. Elevation of Murine Macrophage Protein Kinase C by Activating Doses of Bacterial Lipopolysaccharide. 1985; 66:83a.
    109. Becton DL, Adams DO, Hamilton TA. Characterization of protein Kinase C Activity in Interferon Treated Murine Peritoneal Macrophages. J Cell Phys. 1985; 125::485.
    110. Becton DL, Hamilton TA, Somers SD, Falletta JM, Adams DO. Interferon Gamma Modulates Protein Kinase C in Murine Peritoneal Macrophages. Society for Pediatric Research. 1985.
    111. Becton DL, Hamilton TA, Somers SD, Falletta JM, Adams DO. Interferon Gamma Modulates Protein Kinase C in Murine Peritoneal Macrophages. SSPR. 1984; 890A.
    112. Becton DL, Lowe J, Falletta JM. Lipoid Pneumonia in an Adolescent Female Secondary to use of Lip Gloss. Journal of Pediatrics. 1984; 105::421.
    113. Becton DL, Kinney TR, Falletta JM. Intravenous Immunoglobulin for Treatment of Severe Platelet Alloimmunization. 1983; 900A.
    114. Becton DL, Kinney TR, Falletta JM. Intravenous Immunoglobulin for Treatment of Severe Platelet Alloimmunization. 1983; 900A.
    115. Stine KC, Shrum D, Becton DL. Use of FEIBA for Surgical Procedures in Patients with Severe Hemophilia A and Inhibitors. XXVI International Congress of the World Federation of Hemophilia.
    Becton's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _